Literature DB >> 7594218

Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans.

E Arvat1, J Ramunni, L Gianotti, L Di Vito, M Maccario, F Camanni, E Ghigo.   

Abstract

Beta adrenergic receptors mediate the inhibitory influence of catecholamines on GH secretion in man, likely via stimulation of hypothalamic somatostatin release. To further clarify the role of beta adrenergic receptors in the neural control of GH secretion, in 7 normal females (age 21-27 yr) we studied the interaction of salbutamol (SAL 0.08 mg/kg orally), a beta 2-adrenergic agonist, with GHRH (1 microgram/kg i.v.) and/or galanin (GAL 15 micrograms/kg i.v.), a neuropeptide endowed with a GH-releasing effect which is likely mediated by concomitant stimulation of GHRH- and inhibition of somatostatin-secreting neurons. SAL inhibited the GH response to GHRH (AUC: 282.6 +/- 102.7 vs 1083.6 +/- 176.5 micrograms/l/h, p < 0.05) and, although not significantly, that to GAL (263.9 +/- 103.7 vs 418.4 +/- 70.4 micrograms/l/h). GAL enhanced the GHRH-induced GH rise (2129.5 +/- 362.2 micrograms/l/h, p < 0.05) but SAL pretreatment inhibited this effect (1249.8 +/- 257.1 micrograms/l/h, p < 0.02) so that the GH response to the combined administration of GHRH, GAL and SAL overlapped with that to the neurohormone alone. In conclusion, our results show that the inhibitory influence of beta adrenergic activation on GH secretion overrides the stimulatory one of galanin. They strengthen the view that in man beta-adrenergic receptors and galanin modulate GH secretion having opposite influences aimed to balance the function of the GH-IGF-I axis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594218     DOI: 10.1007/BF03347832

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Beta-adrenergic modulation of growth hormone (GH) autofeedback on sleep-associated and pharmacologically induced GH secretion.

Authors:  M Kelijman; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1989-12       Impact factor: 5.958

2.  Galanin: evidence for a hypothalamic site of action to release growth hormone.

Authors:  A Ottlecz; W K Samson; S M McCann
Journal:  Peptides       Date:  1986 Jan-Feb       Impact factor: 3.750

3.  High-dose porcine galanin infusion and effect on intravenous glucose tolerance in humans.

Authors:  S G Gilbey; J Stephenson; D J O'Halloran; J M Burrin; S R Bloom
Journal:  Diabetes       Date:  1989-09       Impact factor: 9.461

4.  The effect of cholinergic blockade on the growth hormone response to galanin in humans.

Authors:  V K Chatterjee; J A Ball; T M Davis; C Proby; J M Burrin; S R Bloom
Journal:  Metabolism       Date:  1988-11       Impact factor: 8.694

5.  Effect of various adrenergic receptor stimulating and blocking agents on human growth hormone secretion.

Authors:  F Massara; F Camanni
Journal:  J Endocrinol       Date:  1972-08       Impact factor: 4.286

6.  Effects of alpha- and Beta-adrenergic agonists and antagonists on growth hormone secretion in man.

Authors:  E Ghigo; J Bellone; E Arvat; E Mazza; S G Cellat; F Brambilla; E E Müller; F Camanni
Journal:  J Neuroendocrinol       Date:  1990-08-01       Impact factor: 3.627

7.  Selective beta 1-adrenergic receptor-blockade with atenolol enhances growth hormone releasing hormone and mediated growth hormone release in man.

Authors:  N Mauras; R M Blizzard; M O Thorner; A D Rogol
Journal:  Metabolism       Date:  1987-04       Impact factor: 8.694

8.  Noradrenergic regulation of growth hormone secretion in the baboon.

Authors:  J R McWilliam; B S Meldrum
Journal:  Endocrinology       Date:  1983-01       Impact factor: 4.736

9.  Beta-adrenergic stimulation of growth hormone (GH) release in vivo, and subsequent inhibition of GH-releasing factor-induced GH secretion.

Authors:  R J Krieg; S N Perkins; J H Johnson; J P Rogers; A Arimura; M J Cronin
Journal:  Endocrinology       Date:  1988-02       Impact factor: 4.736

10.  Inhibition of hypothalamic somatostatin release by beta-adrenergic antagonists.

Authors:  S B Richardson; S Twente
Journal:  Endocrinology       Date:  1990-02       Impact factor: 4.736

View more
  1 in total

1.  Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Authors:  E Arvat; L Gianotti; J Ramunni; L DiVito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.